Tizanidine Hydrochloride Capsule
Product Images NDC 46708-492

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 46708-492). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsules (Tizanidine 2mg)

Label for Tizanidine Hydrochloride Capsules 2 mg, oral dosage form, containing 30 capsules. Manufactured by Alembic Pharmaceuticals Limited, the label includes a caution that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. It notes storage instructions, a barcode, and space for lot and expiration information.*

FDA Label Image

30 Capsules (Tizanidine 4mg)

Label for Tizanidine Hydrochloride Capsules 4 mg, containing 30 capsules, manufactured by Alembic Pharmaceuticals Limited. The label includes dosage strength, storage instructions, a warning to keep out of children's reach, and a statement that the product is not interchangeable with other Tizanidine tablets.*

FDA Label Image

30 Capsules (Tizanidine 6mg)

Label for Tizanidine Hydrochloride Capsules 6 mg by Alembic Pharmaceuticals Limited. The label indicates a 30 capsule count, prescription use only, and includes a warning that these capsules are not interchangeable with tizanidine tablets or Zanaflex tablets. Packaging instructions and storage information are present, along with manufacturer details from Gujarat, India.*

FDA Label Image

Tizanidine-figure-1.jpg (Tizanidine Figure 1)

A line graph illustrating plasma Tizanidine concentration (ng/mL) over 24 hours post-dosing. It compares four conditions for 2 x 4 mg Tizanidine tablets and capsules, with and without food, showing concentration changes from 0 to 24 hours.*

FDA Label Image

Tizanidine-figure-2.jpg (Tizanidine Figure 2)

A line graph showing improvement in Ashworth Score over 6 hours post-dose for 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis represents improvement, with negative values indicating greater improvement. The horizontal axis shows hours post-dose, with data points at 0, 1, 2, 3, and 6 hours. Error bars indicate variability at each time point.*

FDA Label Image

Tizanidine-figure-3.jpg (Tizanidine Figure 3)

A line graph showing improvement in Ashworth Score comparing Tizanidine (mean dose 28.8 mg) versus placebo across three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph includes mean values and error bars indicating variability at each stage.*

FDA Label Image

Tizanidine-str.jpg (Tizanidine Str)

Chemical structure of Tizanidine Hydrochloride, showing its molecular arrangement including a chlorinated aromatic ring and distinct heterocyclic components with nitrogen and sulfur atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.